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Abstract
Previous studies have reported that context can powerfully modulate the inhibitory effect of an
antipsychotic drug on phencyclidine (PCP)-induced hyperlocomotion (a behavioral test used to
evaluate putative antipsychotic drugs). The present study investigated the experimental conditions
under which environmental stimuli exert their influence through associative conditioning
processes. Experiment 1 examined the extent to which prior antipsychotic treatment in the home
cages affected a drug’s ability to inhibit PCP-induced hyperlocomotion in a novel motor activity
test apparatus. Five days of repeated haloperidol (0.05 mg/kg, sc) and olanzapine (2.0 mg/kg, sc)
treatment in the home cages still potentiated their inhibition of PCP-induced hyperlocomotion (i.e.
sensitization) assessed in a new environment, whereas the clozapine (10.0 mg/kg, sc) treatment
enhanced the development of clozapine tolerance, indicating a lack of environmental modulation
of antipsychotic efficacy. Experiment 2 assessed the impact of different numbers of antipsychotic
administrations in either the home environment or test environment (e.g. 4, 2 or 0) on a drug’s
ability to inhibit PCP-induced hyperlocomotion. Repeated administration of clozapine (5.0 mg/kg,
sc) or olanzapine (1.0 mg/kg, sc) for 4 consecutive days, regardless of where these treatments
occurred, caused a similar level of inhibition on PCP-induced hyperlocomotion. However, 4-day
haloperidol (0.03 mg/kg, sc) treatment in the test apparatus caused a significant higher inhibition
than 4-day home cage treatment. Thus, more exposures to the test environment under the influence
of haloperidol (but not clozapine or olanzapine) cause a stronger inhibition than fewer exposures,
indicating a strong environmental modulation. Collectively, these findings suggest that prior
antipsychotic treatment in one environment could alter later antipsychotic-like response assessed
in a different environment under certain test conditions. Therefore, whether the circumstances
surrounding antipsychotic drug administration exert a powerful control of the expression of
antipsychotic-like efficacy is dependent on specific experimental and drug treatment factors.
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INTRODUCTION
Phencyclidine (PCP) is a psychotomimetic drug that induces various behavioral, emotional,
and cognitive changes in animals by blocking neurotransmission at N-methyl-D-aspartate
(NMDA)-type glutamate receptors. Many animal models of schizophrenia are developed
based on this property of PCP (Javitt and Zukin, 1991; Chen et al., 2011; Javitt et al., 2012).
Among those, PCP-induced hyperlocomotion is a widely used behavioral screening tool to
identify potential antipsychotic-like compounds and study the behavioral and
neurobiological mechanisms of antipsychotic action, as many commonly used antipsychotic
drugs such as haloperidol, clozapine and olanzapine, but not anxiolytics or antidepressants,
suppress PCP-induced hyperlocomotion upon acute drug administration (Redmond et al.,
1999; Porsolt et al., 2010; Zhao et al., 2012a). With repeated drug administration,
antipsychotics (e.g. haloperidol, clozapine, or olanzapine) progressively potentiate inhibition
of repeated PCP-induced hyperlocomotion and prolong this action over several test sessions
(Sun et al., 2009), whereas repeated administration of anxiolytics (e.g. chlordiazepoxide) or
antidepressants (e.g. fluoxetine and citalopram) either does not affect PCP-induced
hyperlocomotion or even enhances it (Redmond et al., 1999). Thus, the repeated PCP-
induced hyperlocomotion test is effective in distinguishing antipsychotic drugs from other
psychotherapeutic drugs and in capturing the time course of an antipsychotic’s clinical
effects (Agid et al., 2006).
Another interesting finding from the repeated PCP-induced hyperlocomotion studies is that
when rats are later given a challenge dose of the drug, those that have been repeatedly
treated with haloperidol or olanzapine exhibit a sensitization effect as they often have lower
PCP-induced hyperlocomotion than vehicle-pretreated rats (Zhang and Li, 2012). In
contrast, rats previously treated with clozapine exhibit higher PCP-induced hyperlocomotion
than those that are treated with clozapine for the first time, indicating a tolerance-like effect
(Feng et al., 2013). These findings indicate that when an antipsychotic drug is given
repeatedly and intermittently, there is often a long-term alteration (increase or decrease) in
its behavioral efficacy, a phenomenon commonly associated with drugs of abuse (Pierce and
Kalivas, 1997; Siegel et al., 2000).
Recent evidence shows that the context surrounding drug administration can powerfully
modulate behavioral efficacy in the PCP-induced hyperlocomotion model (Zhang and Li,
2012; Feng et al., 2013). In those studies, we used a novel across-model transfer paradigm in
which we first treated rats repeatedly with haloperidol, olanzapine or clozapine and tested
them in a conditioned avoidance response model (another behavioral test with high
predictive validity for drugs that have antipsychotic efficacy in humans) for 5 consecutive
days. They were then tested for the expression of haloperidol and olanzapine sensitization
and clozapine tolerance in the PCP-induced hyperlocomotion model. We found that prior
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treatment of haloperidol, olanzapine or clozapine in the avoidance response model did not
change their acute efficacy in the inhibition of PCP-induced hyperlocomotion. When tested
in the PCP model, rats previously treated with these drugs did not show an immediate
stronger (in the case of haloperidol and olanzapine) or weaker (in the case of clozapine)
inhibition of PCP-induced hyperlocomotion than those treated with these drugs for the first
time. However, when tested in the avoidance response model where the original
antipsychotic treatment took place, rats previously treated with these drugs did show a
stronger or weaker inhibition of avoidance response. These results suggest that behavioral
effects of antipsychotic drugs are strongly modulated by the drug test environment and/or
selected behavioral response, exhibiting a context-dependent feature.
It is conceivable that various experimental parameters such as schedule of injections, drug
dose, and similarities between different environmental cues all play a role in the regulation
of environmental control of antipsychotic efficacy. Because the situational impact on
antipsychotic efficacy is a less studied phenomenon, in comparison to a long history and
literature on research on the contextual control of behavioral effects of drugs of abuse
(Siegel, 1975; 1977; Siegel et al., 2000), it is necessary to delineate the exact conditions that
facilitate or diminish the ability of antipsychotics to inhibit PCP-induced hyperlocomotion
and compare this research to the large body of literature on drugs of abuse (Siegel, 1978;
Poulos et al., 1981; Vezina and Stewart, 1984; Anagnostaras and Robinson, 1996; Robinson
et al., 1998; Siegel et al., 2000). One critical yet unaddressed question is whether it is
possible to induce any change in behavioral efficacy of an antipsychotic drug even when
prior treatment occurs in a different environment. In other words, is it possible to observe a
context-independent change in antipsychotic efficacy due to repeated drug administration? If
the answer to this question is yes, this would have important clinical implications. For
example, if manipulation of environmental cues cannot completely prevent the occurrence
of drug-induced change in behavioral efficacy, this would suggest that the repeated
treatment effects may be mainly mediated by the neuroadaptive processes initiated by the
interaction of a drug and its receptors (e.g. dopamine D2 or serotonin 5-HT2A receptors).
Therefore, the treatment settings (e.g. home or hospital) may not be critical for the
expression and maintenance of the therapeutic effects in patients.
In this study, we investigated possible conditions within which contextual control of the
behavioral efficacy of haloperidol, olanzapine and clozapine operates in the PCP-induced
hyperlocomotion model. Two approaches were explored. In Experiment 1, we assessed the
extent to which prior antipsychotic treatment in one environment (Home cage) affected a
drug’s inhibition of PCP-induced hyperlocomotion in another environment (Test
environment). In Experiment 2, we varied the number of pairings of antipsychotic treatment
in either the home environment or test environment (e.g. 4, 2 or 0) and tested how a drug’s
inhibition of the PCP-induced hyperlocomotion was altered by different pairings.
METHODS
Subjects
All experimental treatments and procedures were approved by the Institutional Animal Care
and Use Committee at the University of Nebraska-Lincoln. Adult male Sprague-Dawley rats
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(226–250 g upon arrival, Charles River, Portage, MI) were housed two per cage, in 48.3 cm
× 26.7 cm × 20.3 cm transparent polycarbonate cages under 12-h light/dark conditions (light
on between 6:30 am and 6:30 pm). Room temperature was maintained at 22 ± 1°C with a
relative humidity of 45–60%. Food and water was freely available. Animals were allowed at
least 5 days of habituation to the animal facility before being used in experiments. All
behavioral tests were conducted during the light phase.
Locomotor activity monitoring apparatus
This apparatus has been described before (Sun et al., 2009; Zhao and Li, 2012; Feng et al.,
2013). Sixteen activity boxes were housed in a quiet room. The boxes were 48.3 cm × 26.7
cm × 20.3 cm transparent polycarbonate cages, which were similar to the home cages but
were each equipped with a row of 6 photocell beams (7.8 cm between two adjacent
photobeams) placed 3.2 cm above the floor of the cage. A computer with recording software
(Aero Apparatus Sixbeam Locomotor System v1.4, Toronto, Canada) was used to detect the
disruption of the photocell beams and recorded the number of beam breaks. All experiments
were run during the light cycle.
Experiment 1: Effects of prior antipsychotic treatment in the home cages on the inhibitory
effect of an antipsychotic drug on PCP-induced hyperlocomotion
This experiment examined the impact of the context on antipsychotic efficacy by testing
how prior exposure to an antipsychotic drug in the home cage environment (Home
environment) affects the drug’s efficacy in the inhibition of PCP-induced hyperlocomotion
in a motor activity test environment (Test environment). We compared rats that were
repeatedly treated with haloperidol, clozapine or olanzapine in the home cages for 5
consecutive days with those that were treated with vehicle.
Forty-eight rats were randomly assigned to 1 of 7 groups. From Day 1 to 5, 4 groups of rats
were injected with sterile water in their home cages for 5 consecutive days. They were
denoted as the VEH+VEH (n = 6), VEH+HAL (n = 7), VEH+CLZ (n = 7) and VEH+OLZ
(n = 7) groups. Three groups received haloperidol (0.05 mg/kg, n = 7), clozapine (10.0
mg/kg, n = 7), or olanzapine (2.0 mg/kg, n = 7) treatment in their home cages during this
period. They were denoted as the HAL+HAL, CLZ+CLZ and OLZ+OLZ groups. From Day
6 to 10, all rats were tested for their PCP-induced hyperlocomotion for 5 consecutive days in
the test apparatus. On each of the PCP test days, rats were first injected with either sterile
water (for the VEH+VEH group), haloperidol (0.05 mg/kg, sc, for the VEH+HAL and HAL
+HAL groups), clozapine (10 mg/kg, sc, for the VEH+CLZ and CLZ+CLZ groups), or
olanzapine (2.0 mg/kg, sc, for the VEH+OLZ and OLZ+OLZ groups), and then immediately
placed in the boxes for 30 min. Any drug effect during this period reflects the effect on
spontaneous motor activity. At the end of the 30-min period, they were taken out and
injected with PCP (3.20 mg/kg, sc) and placed back in the boxes for another 60 min. The
drug effect during this period reflects the antipsychotic-like effect on PCP-induced increase
of motor activity (an index of antipsychotic efficacy). Locomotor activity (number of
photobeam breaks) was measured in 5 min blocks throughout the entire 90-min testing
session.
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Experiment 2: Effects of different numbers of drug exposure in the motor activity test
apparatus on the inhibitory effect of an antipsychotic drug on PCP-induced
hyperlocomotion
Experiment 1 did not control total drug exposure between each pair of drug groups.
Therefore, the differential drug effects could be attributed either to this factor or to different
drug-environment (home cage) pairings. In Experiment 2, we controlled the total number of
drug exposure among different groups. In addition, we directly manipulated the number of
drug-environment pairings. Ninety-six rats (run in two cohorts of 48) were first randomly
assigned to 4 groups (n = 24/group) that were subjected to sterile water, haloperidol,
clozapine or olanzapine treatment. Each treatment group was further divided randomly into
3 subgroups (n = 8/group) that differed in the number of drug exposures (i.e., 0, 2, and 4) in
the motor activity test apparatus prior to the 3 PCP-induced hyperlocomotion probe tests.
For the 0-exposure subgroups (VEH-0, HAL-0, CLZ-0, OLZ-0), rats were injected with
water, haloperidol (0.03 mg/kg, sc), clozapine (5.0 mg/kg, sc), or olanzapine (1.0 mg/kg, sc)
followed by PCP (1.6 mg/kg, sc) 30 min later in their home cages for 4 consecutive days.
The antipsychotic drugs and PCP were tested at a lower dose to explore the impact of drug
dosage on the environmental modulation of antipsychotic efficacy in comparison to results
from Experiment 1. In addition, a lower dose would better allow a detection of contextual
control of a drug effect. One day after the last drug injection in the home cages, rats were
tested in the 3 probe tests in the motor activity test apparatus. In each test, rats were injected
with water, haloperidol (0.03 mg/kg, sc), clozapine (5.0 mg/kg, sc), or olanzapine (1.0
mg/kg, sc) followed by PCP (1.6 mg/kg, sc) 30 min later in the test apparatus. Their motor
activities were recorded for the entire 90 min (30 min before and 60 min after the PCP
injection), as done in our previous work (Zhang and Li, 2012). For these subgroups, they
had 0-day experience with the test apparatus before the probe tests.
For the 2-exposure subgroups (VEH-2, HAL-2, CLZ-2, OLZ-2), rats were injected with
water, haloperidol (0.03 mg/kg, sc), clozapine (5.0 mg/kg, sc), or olanzapine (1.0 mg/kg, sc)
and PCP (1.6 mg/kg, sc) at a 30-min interval in the home cages for the first two days, then in
the test apparatus for the last two days; thus, they had a 2-day experience with the test
apparatus prior to the 3 probe tests.
For the 4-exposure subgroups (VEH-4, HAL-4, CLZ-4, OLZ-4), rats had all of their 4-day
drug treatments in the test apparatus prior to the 3 probe tests. As is apparent, the 3
subgroups in each treatment condition (e.g. HAL-0, HAL-2 and HAL-4) had an identical
drug treatment history, and only differed in the number of exposures to the test environment
prior to the probe tests. Thus, any possible differences in locomotion during the probe tests
among the 3 treatment subgroups would reflect the impact of prior drug exposure in the test
environment on the efficacy of a drug in the inhibition of spontaneous motor activity (i.e. 30
min before PCP injection) and PCP-induced hyperlocomotion (i.e. 60 min after PCP
injection).
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Drugs
The injection solution of haloperidol (5 mg/ml ampoules, 5 mg/ml ampoules, Sabex Inc.
Boucherville, Quebec, Canada) was obtained by mixing drugs with sterile water. The
injection solution of phencyclidine hydrochloride (gift from National Institute on Drug
Abuse Chemical Synthesis and Drug Supply Program) was obtained by mixing drugs with
0.9% saline. Clozapine (gift from the NIMH drug supply program) and olanzapine (Toronto
Research Chemical Inc., Canada) were dissolved in 1.5% glacial acetic acid distilled water.
The doses of haloperidol (0.03 or 0.05 mg/kg), olanzapine (1.0 or 2.0 mg/kg), clozapine (5
and 10 mg/kg) and PCP (1.60 or 3.20 mg/kg) were chosen based on our previous work (Sun
et al., 2009; Sun et al., 2010; Zhang and Li, 2012; Zhao et al., 2012b; Feng et al., 2013). All
drugs were administered s.c. at 1.0 ml/kg.
Statistical Analysis
All data were expressed as mean + SEM. Data from the drug test sessions were analyzed
using a mixed analysis of variance (ANOVA) with the between-subjects factors of drug
group and/or drug exposures (e.g. 0, 2 or 4) and the within-subjects factor of test days,
followed by post hoc Fisher’s LSD tests. Differences between groups on the specific drug
test days were analyzed using one-way ANOVAs, followed by post hoc LSD tests. For all
analyses, p < 0.05 was considered statistically significant and all data were analyzed using
SPSS version 21. Because the Fischer's LSD test does not correct for multiple comparisons,
a few instances when p was close to 0.05 should be treated with caution.
RESULTS
Experiment 1: Effects of prior antipsychotic treatment in the home cages on the inhibitory
effect of an antipsychotic drug on PCP-induced hyperlocomotion
Prior drug exposure in the home cage environment potentiated the acute
inhibitory effect of haloperidol and olanzapine on spontaneous motor activity
and PCP-induced hyperlocomotion, but not that of clozapine—Fig. 1 shows the
mean motor activity of the 7 groups of rats during the 30-min pre- and 60-min post-PCP
injection on the 1st drug test day. Acute haloperidol, olanzapine or clozapine treatment
inhibited spontaneous motor activity (Fig. 1A) and PCP-induced hyperlocomotion (Fig. 1B).
One-way ANOVA revealed a significant main effect of group in the first 30 min before PCP
injection, F(6, 41) = 27.20, p < 0.001 and the 60 min after PCP injection, F(6, 41) = 13.44, p
< 0.001. Post-hoc Fisher’s LSD tests revealed that all the antipsychotic treated groups had
significantly lower motor activity than the vehicle group (VEH+VEH) in the first 30 min, p
< 0.003, and all but the VEH+HAL group also had significantly lower motor activity in the
second 60 min, p < 0.002. The VEH+HAL had lower motor activity than the VEH+VEH
group, but the difference was not significant.
Prior haloperidol or olanzapine, but not clozapine, treatment in the home cages also
enhanced their inhibitory effect on spontaneous motor activity and PCP-induced
hyperlocomotion on Day 1. Post-hoc Fisher’s LSD tests on each pair of haloperidol,
olanzapine and clozapine groups showed that the HAL+HAL group had significantly lower
motor activity than the VEH+HAL in the 30 min before PCP, p < 0.02 and in the 60 min
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after PCP injection, p < 0.05. Similarly, the OLZ+OLZ group also had significantly lower
motor activity than the VEH+OLZ group in the first 30 min, p < 0.02 and in the 60 min after
PCP injection, p < 0.005. In contrast, the two clozapine groups did not differ from each
other during both periods. These findings suggest that prior haloperidol and olanzapine
treatment, even in a different environment, still enhanced their acute inhibition of
spontaneous motor activity and PCP-induced hyperlocomotion. The influence of prior
clozapine treatment did not manifest an acute behavioral effect. These findings also indicate
that the expression of haloperidol and olanzapine sensitization induced in the home cage
environment, manifested as an enhanced inhibition of spontaneous motor activity and PCP-
induced hyperlocomotion, was less dependent on the context in which the prior drug
exposure occurred.
Prior clozapine treatment in the home cages enhanced the development of
clozapine tolerance—Fig. 2A shows the mean motor activity of the 7 groups of rats
during the 30-min test period before PCP injection throughout the 5 days of drug testing. A
mixed ANOVA revealed significant main effects of group, F(6, 41) = 12.60, p < 0.001, and
test day, F(4, 164) = 89.04, p < 0.001, and a significant group × day interaction, F(24, 164)
= 8.25, p < 0.001. One-way ANOVAs on each test day indicated that on Day 1, all
antipsychotic treated groups had significantly lower motor activity than the vehicle group,
all p < 0.005, confirming their acute motor suppressive effect. But on Day 5, only the two
olanzapine groups had significantly lower motor activity than the vehicle group, p < 0.005,
whereas the CLZ+CLZ group had a significantly higher motor activity, p < 0.001, indicating
that there was a gradual development of clozapine tolerance in the home cage clozapine
treatment group. This observation was also supported by the finding that the CLZ+CLZ had
significantly higher motor activity than the VEH+CLZ group on days 4 and 5, p < 0.01.
Fig. 2B shows the mean motor activity during the 60-min test period after PCP injection.
Once again, a mixed ANOVA revealed significant main effects of group, F(6, 41) = 27.08, p
< 0.001, and test day, F(4, 164) = 10.58, p < 0.001, and a significant group × day
interaction, F(24, 164) = 4.359, p < 0.001. One-way ANOVAs and post hoc tests on each
test day indicated that all antipsychotic treated groups (except the VEH+HAL group on day
1) showed significantly lower motor activity than the vehicle group throughout the drug test
period, all p < 0.002, confirming their motor suppressive effect on PCP-induced
hyperlocomotion. Except on Day 1, each pair of haloperidol and olanzapine groups did not
differ from each other throughout the rest of the test days. The CLZ+CLZ group had
marginally higher motor activity than the VEH+CLZ groups on Day 5, but this difference
failed to reach significance, p = 0.078.
To better reveal the different impacts of home cage haloperidol and olanzapine exposure
from that of clozapine exposure, we illustrated the time course of the motor activity in
response to haloperidol, olanzapine or clozapine treatment for each drug pair groups (e.g.
VEH+HAL and HAL+HAL) together with the vehicle group in 5-min blocks on Day 1 and
Day 5 (Fig. 3). The potentiated inhibition of prior haloperidol and olanzapine treatment on
the first day was indexed by the finding that the HAL+HAL and OLZ+OLZ groups had
consistently higher motor activity throughout the 90-min test period than the respective
VEH+HAL and VEH+OLZ groups on Day 1. Similarly, the diminished impact of prior
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clozapine on the last day was shown by the consistently reduced motor activity in the CLZ
+CLZ group compared to the VEH+CLZ group on Day 5.
Experiment 2: Effect of different numbers of drug exposure in the motor activity test
apparatus on the inhibitory effect of an antipsychotic drug on PCP-induced
hyperlocomotion
Prior haloperidol exposure in the test apparatus enhanced its efficacy in the
inhibition of PCP-induced hyperlocomotion, while prior clozapine and
olanzapine did not—Figure 4 shows the mean motor activity in the 30 min before and 60
min after PCP injection of the 12 subgroups on their 3 consecutive probe tests. All groups of
rats had identical past drug treatment history by this time but different numbers of exposures
to the test environment. For example, the 4-exposure subgroups had 4 days of antipsychotic
(sterile water) + PCP treatment in the test apparatus (pairing) before the probes; the 2-
exposure subgroups had 2 days of pairing, and the 0-exposure subgroups had not been
exposed to the test apparatus. To examine how different numbers of antipsychotic and test
environment pairings (e.g. 4, 2 or 0) affected a drug’s ability to suppress spontaneous motor
activity and PCP-induced hyperlocomotion, we first conducted a mixed ANOVA (4 drug
conditions × 3 exposure conditions × 3 test days). In the first 30 min of motor activity
testing, there were significant main effects of treatment, F(3, 84) = 11.15, p < 0.001, and
number of test apparatus exposures, F(2, 84) = 25.20, p < 0.001, and a significant treatment
× exposure interaction, F(6, 84) = 4.23, p < 0.001. The main effect of test days was also
significant, F(2, 168) = 33.06, p < 0.001, as was the test × exposure interaction, F(4, 168) =
22.63, p < 0.001. In the 60 min after PCP injection, a mixed ANOVA showed significant
main effects of treatment, F(3, 84) = 37.25, p < 0.001, and number of test apparatus
exposures, F(2, 84) = 3.18, p < 0.05, but no significant treatment × exposure interaction,
F(6, 84) = 1.48, NS. The main effect of test days was significant, F(2, 168) = 6.11, p =
0.005, as were the test × treatment interaction, F(6, 168) = 3.38, p = 0.005, and the test ×
exposure interaction, F(4, 168) = 7.72, p < 0.001.
Because of the significant treatment × exposure interaction and test × exposure interaction,
in order to specify how different numbers of test environment exposures affected each
antipsychotic drug efficacy differently, we conducted mixed ANOVAs comparing the 3
subgroups within each treatment condition over the 3 probe test days (e.g. HAL-0, HAL-2
and HAL-4). For the 3 vehicle subgroups, a mixed ANOVA revealed significant main
effects of group, F(2, 21) = 18.86, p < 0.001, and test, F(2, 42) = 9.15, p < 0.001, and a
significant group × test interaction, F(4, 42) = 8.11, p < 0.001 in the first 30 min. One-way
ANOVAs followed by post hoc tests found that the VEH-0 subgroup had significantly
higher motor activity than the VEH-2 and VEH-4 subgroups on the first two days of testing,
p < 0.01. Because the VEH-0 group had no prior experience of the test apparatus before the
probe tests, the higher motor activity in this subgroup relative to the other 2 vehicle
subgroups could be attributed to the novelty-induced increase in motor activity. In the
second 60 min, neither the group effect, F(2, 21) = 0.59, NS, nor the group × test interaction,
F(4, 42) = 2.176, p = 0.088, were significant. For the 3 haloperidol subgroups, a mixed
ANOVA revealed significant main effects of group, F(2, 21) = 8.99, p < 0.002, and test,
F(2, 42) = 13.08, p < 0.001, and a significant group × test interaction, F(4, 42) = 7.73, p <
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0.001 in the first 30 min. The HAL-4 subgroup had significantly lower motor activity than
the HAL-0 group on the first day, p < 0.005, and lower motor activity than the HAL-0 group
on the second day, p < 0.01. In the second 60 min, the group effect was significant, F(2, 21)
= 6.44, p < 0.01, as were the test effect was significant, F(2, 42) = 11.63, p < 0.001, and the
group × test interaction, F(4, 42) = 4.18, p < 0.01. The HAL-4 subgroup had significantly
lower motor activity than the HAL-0 group on the first day, p < 0.005 and the last day, p <
0.05. These results suggest that repeated haloperidol exposure in the test apparatus enhanced
the efficacy of HAL in the inhibition of spontaneous motor activity and PCP-induced
hyperlocomotion in the same environment.
For the 3 clozapine subgroups, a mixed ANOVA showed no significant main effect of
group, F(2, 21) = 0.86, NS, but a significant group × test interaction, F(4, 42) = 3.44, p <
0.02 in the first 30 min. One-way ANOVAs on each test day did not find a significant group
effect, all p > 0.06. In the following 60 min, the group effect, the test effect and their
interaction were all nonsignificant, p > 0.075. These results indicate that repeated clozapine
exposure in the test apparatus did not alter its efficacy in the inhibition of spontaneous motor
activity and PCP-induced hyperlocomotion in the same test environment.
For the 3 olanzapine subgroups, in the first 30 min, a mixed ANOVA revealed significant
main effects of group, F(2, 21) = 8.86, p < 0.002, and test, F(2, 42) = 14.51, p < 0.001, and a
signficiant group × test interaction, F(4, 42) = 6.65, p < 0.001. The OLZ-0 subgroup had
significantly higher motor activity than the other two OLZ subgroups on the first day, p <
0.001, and higher motor activity than the OLZ-2 subgroup on the third day, p < 0.05. In the
following 60 min, the group effect, the test effect and their interaction were all
nonsignificant, p > 0.24. These results suggest that repeated olanzapine exposure in the test
apparatus primarily enhanced its efficacy in the inhibition of spontaneous motor activity.
Taken together, results from this experiment suggest that repeated pairing of haloperidol and
olanzapine treatment with the test environment enhanced their efficacy of inhibition of
spontaneous motor activity. Repeated pairing of haloperidol treatment with the test
environmental also enhanced its inhibition of PCP-induced hyperlocomotion, while repeated
clozapine or olanzapine and environment pairing had little effect on this measure.
DISCUSSION
The present study provides evidence that specific experimental parameters and drug
treatment play a role in determining whether the contextual cues associated with
antipsychotic drug administration would exert control over the expression of antipsychotic
efficacy. In Experiment 1, we found that repeated administration of haloperidol (0.05 mg/kg,
sc) and olanzapine (2.0 mg/kg, sc), even in the home cages, potentiated their inhibition of
PCP (3.20 mg/kg, sc)-induced hyperlocomotion in the motor activity test boxes (a novel
environment). Furthermore, relative to the VEH+CLZ group, pretreatment with clozapine in
the home cage decreased its effectiveness on spontaneous activity over the 5-day test period
in the motor test environment. These findings suggest that under certain test conditions,
antipsychotic sensitization or tolerance could be less impacted by environmental cues. This
conclusion was consistent with our finding in Experiment 2 that repeated administration of
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clozapine (5.0 mg/kg, sc) or olanzapine (1.0 mg/kg, sc) for 4 consecutive days, regardless of
where these treatments occurred (e.g. 2 days in the home cage and 2 days in the test
apparatus; or 4 days in the home cage and 0 day in the test apparatus), had a similar level of
inhibition on PCP (1.6 mg/kg, sc)-induced hyperlocomotion over the 3-day probe test
period. In contrast, the observation that rats that received 4-day haloperidol (0.03 mg/kg, sc)
treatment in the test apparatus had significantly lower motor activity than those that received
0-day treatment, in spite of their identical drug treatment history, does support the notion
that the environment associated with repeated drug administration could powerfully
modulate the expression of antipsychotic efficacy.
The contextual control of the behavioral efficacy of an antipsychotic drug is a relatively less
studied topic. Evidence supporting both context independence and context dependence has
been reported in the literature. For example, Sanger (1985) reported that repeated
haloperidol or clozapine treatment, whether inside the test environment or outside, has little
impact on the development of haloperidol sensitization or clozapine tolerance in a
conditioned avoidance response model. However, in a similar conditioned avoidance
response test, we showed that home-cage haloperidol (0.05 mg/kg) and olanzapine (1.0
mg/kg) treatment did not increase their behavioral efficacy of inhibition of avoidance
response, indicating a context-dependent feature (Li et al., 2009; Sparkman and Li, 2012).
Similarly, Schmidt’s group also reported that intermittent haloperidol treatment and repeated
catalepsy testing caused an intensification of catalepsy over time and that this increase was
completely context specific, as context changes abolished catalepsy sensitization (Amtage
and Schmidt, 2003; Klein and Schmidt, 2003). Therefore, the environmental impact of a
drug effect is dependent on the specific test conditions, including the selected behavioral
responses, drug types, drug doses, number of drug treatments, etc. It is not a question of
whether environmental cues play a role in the regulation of a drug effect, but under what
exact conditions.
This point was also supported in our recent study of the environmental and behavioral
controls of the expression of clozapine tolerance (Feng et al., 2013). Using an across-model
transfer paradigm, we first treated rats repeatedly with clozapine (2.5–10.0 mg/kg, sc) in
either the conditioned avoidance response task or the PCP (1.6 mg/kg, sc)-induced
hyperlocomotion test for 5 consecutive days. We then switched them to a different test and
tested them under clozapine for another 5 days. When switching from the avoidance task to
the PCP test, rats previously treated with clozapine in the avoidance task did not show an
immediately weakened inhibition of PCP-induced hyperlocomotion compared to those
treated with clozapine for the first time, but showed a significantly weaker inhibition over
time. This finding matches perfectly with our finding from Experiment 1, suggesting that
change of environment only affects the acute effect of clozapine, but has no effect on its
tolerance effect.
In our previous study (Sun et al., 2009), we showed that repeated administration of
clozapine at 10.0 mg/kg maintained its inhibition of spontaneous motor activity and PCP-
induced hyperlocomotion over the 5 test days, a finding replicated in the present study
(Figure 2B). Because the VEH+PCP group showed a progressive increase in motor activity
over days, the persistent inhibition in the VEH+CLZ group indicates a sensitization-like
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effect, especially during the repeated drug test phase. This sensitization-like effect seems
weaker in the CLZ+CLZ group relative to the VEH+CLZ group, as indicated by the
significantly higher motor activity in the CLZ+CLZ group compared to the VEH+CLZ
group in the first 30 min of testing on Day 4 and 5, and marginally significant higher motor
activity in the second 60 min of testing on Day 5. Although we interpreted this finding as
reflecting the home cage clozapine-induced tolerance development, it could also be
interpreted as the consequence of home cage clozapine treatment that prevented the
appearance of a sensitization-like effect. The exact nature of such a prior clozapine effect
needs to be further investigated.
Studies on contextual control of drug effects typically compare a “paired” group (a group
that receives drug injection in the test environment) with an “unpaired” group (a group that
receives vehicle injection in the test environment, and drug in the home cage) (Poulos and
Hinson, 1982; Amtage and Schmidt, 2003). The influence of environment is assessed on a
test day, when all animals receive a challenge injection of the drug in the test environment.
If a stronger drug effect was detected in the “paired” group, this would suggest that
environmental stimuli have an influence on the drug effect (Robinson et al., 1998).
Experiment 2 used this approach and found that only repeated pairings of haloperidol
treatment in the test apparatus enhanced the efficacy of haloperidol in the inhibition of
spontaneous motor activity and PCP-induced hyperlocomotion, as the HAL-4 subgroup had
significantly lower motor activity than the HAL-0 group in the 30 min and second 60 min
test periods. This enhanced HAL effect occurred because HAL, administered at this low
dose (0.03 mg/kg) in the test environment for the first time, was unable to inhibit novelty-
induced increase in motor activity as shown in the HAL-0 group. In contrast, repeated
clozapine/olanzapine pairings in the test environment produced little alteration of their
effects. These results further suggest that the specific conditions govern the impact of
environmental cues on a drug effect. Under the current condition, the circumstances
surrounding drug administration had a large impact on the behavioral efficacy of
haloperidol, but not that of clozapine and olanzapine. The reason for this differential impact
on different antipsychotic drugs is not entirely clear. One possibility is that haloperidol has a
stronger antagonist action on D2 receptor and tighter D2 receptor binding than olanzapine
and clozapine (Kapur and Seeman, 2000), and multiple behavioral effects mediated by
dopamine systems are typically modulated by environmental cues (Anagnostaras and
Robinson, 1996; Robinson et al., 1998; Anagnostaras et al., 2002).
One limitation of the present study is that only one dose of each antipsychotic drug was
tested in each experiment. Therefore, the results from this study should be considered
together with, and also in the context of, evidence from our previous studies (Li et al., 2009;
Sparkman and Li, 2012; Zhang and Li, 2012; Feng et al., 2013). Overall the evidence seems
to support the notion that environmental cues and behavioral responses could have a
powerful impact on the inhibitory effect of an antipsychotic drug on PCP-induced
hyperlocomotion and on conditioned avoidance responding (two well-validated behavioral
measures of antipsychotic-like activity). But such an impact could be limited by certain test
conditions, such as the degree of similarity between different test environments, drug doses,
and number of drug treatments.
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Figure 1. Effect of home cage antipsychotic treatment on the acute inhibitory effect of
antipsychotic drugs on PCP-induced hyperlocomotion tested in a new motor activity apparatus
Locomotor activity was measured for 30 min after sterile water (VEH), haloperidol (0.05
mg/kg), clozapine (10.0 mg/kg), or olanzapine (2.0 mg/kg) injection (A) and 60 min after
PCP (3.2 mg/kg) injection (B) and expressed as mean + SEM for each group. * p < 0.05
relative to the VEH+VEH group; # p < 0.05 relative to the corresponding control groups that
were treated with vehicle in the home cages (i.e. VEH+HAL or VEH+OLZ).
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Figure 2. Effect of home cage antipsychotic treatment on the inhibitory effect of antipsychotic
drugs on PCP-induced hyperlocomotion throughout the 5 days of drug testing
(A) Locomotor activity was measured for 30 min after sterile water (VEH), haloperidol
(0.05 mg/kg), clozapine (10.0 mg/kg), or olanzapine (2.0 mg/kg) injection and expressed as
mean + SEM for each group. (B) Locomotor activity was measured for 60 min after PCP
injection and expressed as mean + SEM. * p < 0.05 relative to the VEH+VEH group; # p <
0.05 relative to the corresponding control groups that were treated with vehicle in the home
cages (i.e. VEH+HAL or VEH+OLZ).
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Figure 3. Effect of home cage antipsychotic treatment on the inhibitory effect of antipsychotic
drugs on PCP-induced hyperlocomotion on Day 1 and Day 5 of drug testing
Locomotor activity was measured in 18 5-min blocks for the two haloperidol groups (VEH
+HAL and HAL+HAL) (A), two olanzapine groups (VEH+OLZ and OLZ+OLZ) (B), and
two clozapine groups (VEH+CLZ and CLZ+CLZ) (C), together with the vehicle groups.
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Figure 4. Prior haloperidol exposure in the test apparatus enhanced its efficacy of inhibition of
PCP-induced hyperlocomotion, while prior clozapine and olanzapine did not
Locomotor activity in the 30 min before (A) and 60 min after PCP injection (B) of the 12
subgroups across the three days of PCP-induced hyperlocomotion testing are expressed as
mean + SEM. # p < 0.05 relative to the corresponding 4-exposure subgroup; $ p < 0.05
relative to the corresponding 2-exposure subgroup.
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